Neurogene Inc. (NGNE) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Neurogene Inc. (NGNE)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

18.54

0.65 (3.63%)

At close: Jan 15, 2025, 1:36 PM

undefined% (undefined)

Bid	18.5
Market Cap	389.01M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-4.09
PE Ratio (ttm)	-4.53
Forward PE	n/a
Analyst	Buy

Ask	18.61
Volume	29,720
Avg. Volume (20D)	400,480
Open	18.59
Previous Close	17.89
Day's Range	18.14 - 19.14
52-Week Range	14.44 - 74.49
Beta	undefined

About NGNE

Neurogene Inc. develops life-changing genetic medicines for patients and their families affected by neurological diseases. Its product candidate includes NGN-401, an investigational AAV9 gene therapy for the treatment of Rett syndrome; and NGN-101 to treat neuronal ceroid lipofuscinosis subtype 5 batten disease. The company is headquartered in New York, New York....

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Mar 7, 2014

Employees 91

Stock Exchange NASDAQ

Ticker Symbol NGNE

Website https://www.neurogene.com

Analyst Forecast

According to 6 analyst ratings, the average rating for NGNE stock is "Buy." The 12-month stock price forecast is $60, which is an increase of 223.59% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Why Price Moved

1 month ago · Source

-42.58%

Neurgogene shares are trading lower after the comp... Unlock content with Pro Subscription

2 months ago · Source

-44.08%

Neurogene shares are trading lower. The company issued interim efficacy data from its first four low-dose pediatric participants in NGN-401 gene therapy clinical trial for Rett Syndrome.

News

1 month ago · businesswire.com

Neurogene Reports Third Quarter 2024 Financial Results and Highlights Recent Updates

NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, tod...

1 month ago · benzinga.com

Neurogene, Nvidia And Other Big Stocks Moving Lower In Monday's Pre-Market Session

U.S. stock futures were mixed this morning, with the Dow futures falling more than 100 points on Monday.

1 month ago · businesswire.com

Neurogene Provides Update on NGN-401 Gene Therapy Clinical Trial for Rett Syndrome

2 months ago · marketbeat.com

Neurogene Stock Plummets 44%: Is All Hope Lost for This Biotech?"

Bad news on Monday caused the pharmaceutical company's shares to drop massively in after-hours trading, and they continued to slide through Tuesday. So, what was it that sent shares of Neurogene, a st...

2 months ago · benzinga.com

Neurogene Stock Tanks After Adverse Event In Early-Stage Rett Syndrome Gene Therapy Trial

On Monday, Neurogene Inc. NGNE released interim clinical data in the first four participants in the low-dose cohort of its ongoing Phase 1/2 open-label trial of NGN-401 gene therapy for female pediat...

AI Score

Unlock

AI Score

AI Score

Unlock

AI Score

About NGNE

Analyst Forecast

1 month ago · businesswire.com

1 month ago · benzinga.com

1 month ago · businesswire.com

2 months ago · marketbeat.com

2 months ago · benzinga.com

2 months ago · businesswire.com

2 months ago · businesswire.com

2 months ago · businesswire.com